Integration of agentic computational systems enables the early-stage definition of key clinical and biological success criteria, accelerating discovery timelines, improving scalability, and increasing the likelihood of success. REHOVOT, Israel , June 24, 2026 /PRNewswire/ -- Evogene Ltd. (NASDAQ: EVGN ) (TASE: EVGN), a computational biology and chemistry company leveraging artificial intelligence (AI) to discover and develop innovative small-molecule products for the pharmaceutical and agricultural industries, today announced the successful completion of a significant milestone in its second collaboration with Google Cloud. This milestone marks the integration of agentic computational systems within Evogene's ChemPass AI™ platform, designed to rapidly and efficiently identify key success requirements at the earliest stages of small-molecule development. These new capabilities are expected to enable the selection of molecules that meet product definition requirements at the early stages of the discovery phase, with the goal of accelerating discovery timelines, improving scalability and most importantly, significantly enhancing the overall probability of success. Successful small-molecule development requires identifying candidates that satisfy a broad and complex set of biological, chemical, clinical and commercial requirements. These requirements are defined by the Target Product Profile (TPP) and are critical to the eventual success of any development program. Because many of these requirements are traditionally evaluated only in the later stages of development, and since researchers often fail to anticipate these downstream challenges during early candidate selection, discovery programs often face costly delays, inefficient allocation of R&D resources, high attrition rates, and increased development risk. To address these challenges, the enhanced ChemPass AI™ engine, enabled by Google's Gemini models and Gemini Enterprise Agent Platform, is designed to enable earlier and deeper biological TPP profiling, with the goal of identifying the critical criteria a molecule must satisfy to progress successfully. This capability is driven by a workflow of autonomous AI agents that integrate structural, biological, chemical and clinical data to independently profile these targets. ChemPass is designed to address a broad number of requirements simultaneously throughout the molecule design and generation process. The integration of these new and existing capabilities is intended to allow research teams to anticipate downstream requirements and prioritize compounds with the highest development and commercial potential from the outset of the discovery phase, before significant resources are committed. The milestone was achieved through the ongoing collaboration between Evogene and Google Cloud. Google Cloud's enterprise-grade AI infrastructure and platforms provide the foundation for building scalable, next-generation autonomous discovery capabilities. The integration demonstrates how advanced cloud-based AI technologies may accelerate innovation across the life sciences sector. This achievement represents an important step in Evogene's vision to advance molecular discovery and optimization through artificial intelligence. The Company is advancing toward increasingly autonomous computational systems designed to predict key success requirements at the earliest stages of development. Boaz Maoz, Managing Director, Google Cloud Israel, commented: "We are excited to see how Evogene is leveraging Google Cloud's full AI stack to redefine the life sciences sector. By using our Gemini models and embarking on agentic AI, Evogene is positioned to innovate and significantly accelerate the discovery of new molecules, demonstrating the transformative power of AI in streamlining complex biological and chemical research." Ofer Haviv, President and CEO of Evogene, stated: "This milestone advances our vision to redefine molecular discovery and optimization through AI. Google Cloud's technology provides a robust foundation for scaling these capabilities across our pipeline and future collaborations. By integrating advanced AI agents into ChemPass AI™, we believe we can generate richer target profiles earlier in discovery. This is intended to allow us to anticipate downstream requirements and prioritize high-potential candidates before committing significant resources, with the goal of moving us closer to autonomous computational systems that predict key success requirements at the earliest stages. As we enter this next phase, we believe these new capabilities may position us to address complex proteins that currently represent a challenge in the development of new therapies." About Evogene Ltd.: Evogene Ltd. (NASDAQ: EVGN ) (TASE: EVGN) is a pioneering company in computational, specializing in the generative design of small molecules for drug development and ag-chemical products. At the core of its technology is ChemPass, a proprietary gen